Tenax CFO buys 5,675 shares at $1.935 avg price
TENAX THERAPEUTICS’ chief financial officer bought additional TENX shares and disclosed a large option position with long-term, time-based vesting.
Rhea-AI Filing Summary
TENAX THERAPEUTICS, INC. (TENX) reported that Chief Financial Officer Thomas R. Staab II purchased 5,675 shares of common stock in the open market on September 11, 2026 at a weighted average price of $1.935 per share, bringing his direct common stock holdings to 15,675 shares.
He also holds a stock option covering 450,000 shares of common stock at an exercise price of $11.95 per share, expiring on May 11, 2036; according to the vesting schedule, 25% vest on May 11, 2027 and the remainder vest in substantially equal monthly installments over 36 months, subject to continued employment. No Rule 10b5-1 trading plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 5,675 shares
Net Buy
2 txns
Insider
STAAB THOMAS R II
Role
Chief Financial Officer
Bought
5,675 shs ($11K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1 | 5,675 | $1.935 | $11K |
| holding | Stock Option (right to buy) F2 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 15,675 shares (Direct);
Stock Option (right to buy) — 450,000 contracts (Direct)
Footnotes (2)
- F1. This transaction was executed in multiple trades at prices ranging from $1.90 to $1.95. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- F2. The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment.
Key Figures
Shares purchased: 5,675 shares
Purchase price (weighted average): $1.935 per share
Direct holdings after transaction: 15,675 shares
+5 more
8 metrics
Shares purchased
5,675 shares
Common stock bought by CFO on September 11, 2026
Purchase price (weighted average)
$1.935 per share
Open-market purchase range $1.90–$1.95 on September 11, 2026
Direct holdings after transaction
15,675 shares
CFO’s direct common stock position following the reported purchase
Stock option exercise price
$11.95 per share
Exercise price of stock option on 450,000 underlying TENAX common shares
Underlying shares in option
450,000 shares
Common shares underlying the CFO’s stock option position
Option expiration date
May 11, 2036
Expiration of the reported stock option position
Initial vesting portion
25%
Portion of options vesting on May 11, 2027, subject to continued employment
Remaining vesting period
36 months
Period over which remaining options vest in substantially equal monthly installments
Key Terms
weighted average price, stock option (right to buy), vest
3 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock option (right to buy) financial
"Security title is Stock Option (right to buy) with underlying Common Stock."
vest financial
"The options vest and become exercisable as follows: 25% vest on May 11, 2027..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did TENX report for its CFO on September 11, 2026?
TENAX THERAPEUTICS reported that its Chief Financial Officer Thomas R. Staab II purchased 5,675 shares of common stock on September 11, 2026 at a weighted average price of $1.935 per share in an open-market transaction.
What is the size and strike price of the CFO’s stock option position in TENX?
The filing shows a stock option held by the CFO covering 450,000 underlying shares of TENAX common stock with an exercise price of $11.95 per share and an expiration date of May 11, 2036.
What is the vesting schedule for the CFO’s TENX stock options?
According to the disclosure, 25% of the options vest on May 11, 2027, and the remaining options vest in substantially equal installments on each monthly anniversary of the grant date over 36 months, subject to the CFO’s continued employment.
At what prices were the TENX CFO’s trades executed on September 11, 2026?
The filing states that the transaction was executed in multiple trades at prices ranging from $1.90 to $1.95 per share, with the reported $1.935 figure representing a weighted average price for the 5,675 shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
